Clinical trials
Myasthenia Gravis clinical trials
Below are recruiting myasthenia gravis clinical trials, each written for real people, not researchers. We’re tracking 106 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07136844Recruiting
Walking and arm movement study for nerve and muscle conditions
This study uses motion analysis to understand walking and arm function in adults with certain neurological or metabolic diseases. The goal is to find patterns that help doctors better manage these conditions.
LiègeAges 18 years+ - NCT07146425Recruiting
Building a digital assessment model for myasthenia gravis
This study uses digital tools like questionnaires and smartphone tests to measure how myasthenia gravis affects you. It aims to create a better way for doctors to track your symptoms and adjust treatment.
ShanghaiAges 18 years+ - NCT07246564RecruitingPhase 4
Rozanolixizumab for Generalized Myasthenia Gravis in Chinese Adults
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
BeijingAges 18 years+ - NCT07250750RecruitingPhase 1/Phase 2
IM-101 for generalized and ocular myasthenia gravis
This study tests a new medicine called IM-101 in people with myasthenia gravis (MG), a muscle weakness condition. It aims to see if it can safely help manage symptoms.
Altamonte Springs, FloridaAges 18–74 - NCT06414954RecruitingPhase 2
Study of an oral medication for myasthenia gravis
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
Carlsbad, CaliforniaAges 18 years+ - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age - NCT07570589Recruiting
Tracking myasthenia gravis symptoms on rozanolixizumab treatment
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
Nice, Alpes-maritimesAges 18 years+ - NCT06447597RecruitingPhase 2/Phase 3
Study of B007 for Generalized Myasthenia Gravis
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
BeijingAges 18–70 - NCT06540144Enrolling by invitationPhase 3
Extended rozanolixizumab treatment for children with myasthenia gravis
This study continues treatment for children who took part in an earlier trial (MG0006) for generalized myasthenia gravis. It tests 6-week cycles of a drug called rozanolixizumab to see if it continues to work well and stay safe.
BolognaAges 2 years+ - NCT06359041RecruitingPhase 1/Phase 2
CABA-201 cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy called CABA-201 for people with generalized myasthenia gravis. It aims to reset the immune system to reduce muscle weakness and improve daily functioning.
Orange, CaliforniaAges 18–70 - NCT07039916RecruitingPhase 3
Study of IMVT-1402 for mild to severe generalized myasthenia gravis
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
Huntsville, AlabamaAges 18–80 - NCT06744920RecruitingPhase 3
New drug for generalized myasthenia gravis
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
Phoenix, ArizonaAges 18–85 - NCT04806620Recruiting
Online app study for brain inflammation lifestyle data
This study uses a digital platform (app/website) to collect lifestyle and symptom information to better understand brain inflammation. You may qualify if you have certain conditions like Long COVID, migraines, autoimmune disease, inflammatory gut issues, mood disorders, or if you are a healthy comparison person.
Delafield, WisconsinAges 2 years+ - NCT04833894RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Chicago, IllinoisAges 2–18 - NCT05868837RecruitingPhase 3
Rituximab for myasthenia gravis in people with moderate symptoms
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
RomaAges 18 years+ - NCT06055959RecruitingPhase 2/Phase 3
Zilucoplan for children with generalized myasthenia gravis
This study tests a new daily shot (zilucoplan) for children and teens with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. It aims to see if the drug is safe and helps improve strength and daily functioning.
Chicago, IllinoisAges 12–17 - NCT06064695Recruiting
Electrical muscle stimulation exercise for myasthenia gravis
This study tests if whole-body electrical muscle stimulation exercise can help adults with generalized myasthenia gravis. It also enrolls healthy controls for comparison. If you have MG and can stand for about 15 minutes, this may be an option.
Fairway, KansasAges 18 years+ - NCT06392386RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Charlotte, North CarolinaAges 2–17 - NCT07647510RecruitingPhase 3
Testing Claseprubart for Generalized Myasthenia Gravis
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
Fayetteville, North CarolinaAges 18–80 - NCT06607627RecruitingPhase 3
Testing gefurulimab in children with generalized myasthenia gravis
This study tests a new drug called gefurulimab in children and teens with generalized myasthenia gravis (a disease that causes muscle weakness). It looks at how safe and effective the drug is, and how it works in the body.
Washington D.C., District of ColumbiaAges 6–17 - NCT06704269RecruitingPhase 1/Phase 2
YTB323 for treatment-resistant generalized myasthenia gravis
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
Orange, CaliforniaAges 18–65 - NCT06435312Enrolling by invitationPhase 3
Studying zilucoplan for children with generalized myasthenia gravis
This study gives an injectable medicine called zilucoplan to children who were part of an earlier trial and could benefit from more treatment. It aims to see if zilucoplan is safe and helpful for young patients with generalized myasthenia gravis.
MilanAges 12 years+ - NCT06967480Recruiting
Early ravulizumab for recent-onset generalized myasthenia gravis
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
BergamoAges 18 years+ - NCT07249632RecruitingPhase 3
Study of Telitacicept for Eye Muscle Weakness from Myasthenia Gravis
This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.
Beijing, Beijing MunicipalityAges 12–80
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myasthenia gravis?
- Yes. Clin2 currently lists 106 recruiting myasthenia gravis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myasthenia gravis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myasthenia gravis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.